RE:RE:RE:psst...Charly50 wrote: In fact, it would be appropriate with the option and DSU allocation to also present a license deal to the shareholders.
In other words, to link the company's own business success to the allocation. After all, the allotment price is in US dollars.
DF it's true, next week is Christmas.
Given we are contextualizing today Charly, let's go there. Yes, next week is Christmas. Last Friday afternoon's sudden last minute runup and today's announcement are correlated. I'm not sure if the irony of when Christmas is arriving is amusing...but whatever. You having conversations with the company CEO and thinking you therefore are part of the whisper network setup, is interesting. I'll just leave that, at that.
Meanwhile, there's the matter of how Extendicare "managed" Covid in those seniors centres across Canada. I'll let you do some research on that. Hopefully our new IR guy learned a few things. As for WHEN the presentation of the DEAL to shareholders...better be soon. Better also be very enriching for those of us who've been waiting for what seems like forever for monetization of the science to happen.
DF
(P.S. you'll know you are the smartest guy in the room when you can separate the BS from who the BS producer is. Until then, I don't care who you've talked with and what biases you need reinforced. Just be respectful of the fact that there is the science and there is the business and this company historically has done much better at one of those things than the other of those things. Calling BULL is a perfectly reasonable thing to do when you know there are weaknesses being glossed over. Merry Christmas! (sincerely))
DF